A drug compounder in Tennessee received an FDA warning letter for preparing drug products in insanitary conditions.

The FDA issued a warning letter to Nartex Laboratories, a manufacturer of homeopathic drugs, for validation and testing failures.

Merck announced yesterday that it is discontinuing its phase 3 nonsmall-cell lung cancer trial of Keytruda (pembrolizumab) in combination with Bristol Myers Squibb’s (BMS) Yervoy (ipilimumab), citing an unfavorable benefit-risk profile.